BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 26141343)

  • 1. Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
    Pernot S; Artru P; Mithieux F; Marsot J; Watkin E; Pellerin O; Lledo G; Chalabreysse P; Desramé J; Taieb J
    Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):e73-7. PubMed ID: 26141343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
    Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
    Martin RC; Scoggins CR; Tomalty D; Schreeder M; Metzger T; Tatum C; Sharma V
    J Gastrointest Surg; 2012 Aug; 16(8):1531-8. PubMed ID: 22528576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
    Richardson AJ; Laurence JM; Lam VW
    J Vasc Interv Radiol; 2013 Aug; 24(8):1209-17. PubMed ID: 23885916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.
    Bhutiani N; Akinwande O; Martin RC
    World J Surg; 2016 May; 40(5):1178-90. PubMed ID: 26711640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.
    Jones RP; Malik HZ; Fenwick SW; Terlizzo M; O'Grady E; Stremitzer S; Gruenberger T; Rees M; Plant G; Figueras J; Albiol M; Adam R; Awad S; Poston GJ
    Eur J Surg Oncol; 2016 Dec; 42(12):1866-1872. PubMed ID: 27561844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization.
    Scevola G; Loreni G; Rastelli M; Sposato S; Ramponi S; Miele V
    Med Oncol; 2017 Mar; 34(3):37. PubMed ID: 28160267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer.
    Narayanan G; Barbery K; Suthar R; Guerrero G; Arora G
    Anticancer Res; 2013 May; 33(5):2077-83. PubMed ID: 23645758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study.
    Iezzi R; Marsico VA; Guerra A; Cerchiaro E; Cassano A; Basso M; Devicienti E; Rodolfino E; Barone C; Bonomo L
    Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1523-31. PubMed ID: 25799948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.
    Pernot S; Pellerin O; Artru P; Montérymard C; Smith D; Raoul JL; De La Fouchardière C; Dahan L; Guimbaud R; Sefrioui D; Jouve JL; Lepage C; Tougeron D; Taieb J;
    Br J Cancer; 2020 Aug; 123(4):518-524. PubMed ID: 32507854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorouracil, leucovorin and irinotecan combined with intra-arterial hepatic infusion of drug-eluting beads preloaded with irinotecan in unresectable colorectal liver metastases: side effects and results of a concomitant treatment schedule. Clinical investigation.
    Kekez D; Badzek S; Prejac J; Gorsic I; Golem H; Librenjak N; Perkov D; Smiljanic R; Plestina S
    Tumori; 2014; 100(5):499-503. PubMed ID: 25343542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study.
    Venturini M; Sallemi C; Agostini G; Marra P; Cereda S; Reni M; Aldrighetti L; De Cobelli F; Del Maschio A
    Br J Radiol; 2016 Nov; 89(1067):20160247. PubMed ID: 27558984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Experience with 70-150 μm Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases.
    Akinwande O; Scoggins C; Martin RC
    Anticancer Res; 2016 Jul; 36(7):3413-8. PubMed ID: 27354601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population.
    Huppert P; Wenzel T; Wietholtz H
    Cardiovasc Intervent Radiol; 2014 Feb; 37(1):154-64. PubMed ID: 23670568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).
    de Baere T; Tselikas L; Boige V; Ducreux M; Malka D; Goéré D; Benahim E; Deschamps F
    Bull Cancer; 2017 May; 104(5):402-406. PubMed ID: 27993355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI(®)) for colorectal liver metastases does not predict tumour destruction or long-term outcome.
    Jones RP; Stättner S; Dunne DF; O'Grady E; Smethurst A; Terlizzo M; Malik HZ; Fenwick SW; Poston GJ
    Eur J Surg Oncol; 2013 Oct; 39(10):1122-8. PubMed ID: 23928482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.
    Tanaka T; Sato T; Nishiofuku H; Masada T; Tatsumoto S; Marugami N; Otsuji T; Kanno M; Koyama F; Sho M; Kichikawa K
    BMC Cancer; 2019 Aug; 19(1):758. PubMed ID: 31370815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: results of a phase I/II study.
    Nishiofuku H; Tanaka T; Matsuoka M; Otsuji T; Anai H; Sueyoshi S; Inaba Y; Koyama F; Sho M; Nakajima Y; Kichikawa K
    J Vasc Interv Radiol; 2013 Jan; 24(1):56-65. PubMed ID: 23194749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects.
    Fiorentini G; Aliberti C; Benea G; Montagnani F; Mambrini A; Ballardini PL; Cantore M
    Hepatogastroenterology; 2008; 55(88):2077-82. PubMed ID: 19260480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study.
    Martin RC; Joshi J; Robbins K; Tomalty D; Bosnjakovik P; Derner M; Padr R; Rocek M; Scupchenko A; Tatum C
    Ann Surg Oncol; 2011 Jan; 18(1):192-8. PubMed ID: 20740319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.